Anzeige
Mehr »
Login
Samstag, 10.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Super Gelegenheit! 4.000%-Kandidat mit letzter Gelegenheit vor dem Big Bang!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DJ26 ISIN: US03767D1081 Ticker-Symbol: HQ8F 
Tradegate
07.04.21
09:35 Uhr
4,540 Euro
-0,060
-1,30 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
APOLLO ENDOSURGERY INC Chart 1 Jahr
5-Tage-Chart
APOLLO ENDOSURGERY INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,6604,78012:39
4,6404,84009.04.
ACCESSWIRE
1.122 Leser
Artikel bewerten:
(2)

Apollo Endosurgery, Inc.: Apollo Endosurgery to Present at HC Wainwright Global Life Sciences Conference

AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences Conference taking place virtually March 9-10, 2021.

Management will provide a pre-recorded presentation which will be available to registered investors on demand via the conference website. As part of the conference agenda, Chief Executive Officer Chas McKhann and Chief Financial Officer Stefanie Cavanaugh will be available for one on one meetings with investors.

For more information about the conference or to arrange a meeting, please contact your H.C. Wainwright representative or Matt Kreps, Investor Relations for Apollo Endosurgery, at mkreps@darrowir.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on the development of next-generation, less invasive devices to advance gastrointestinal therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, X-TackTM Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon.

Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contact:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.



View source version on accesswire.com:
https://www.accesswire.com/632991/Apollo-Endosurgery-to-Present-at-HC-Wainwright-Global-Life-Sciences-Conference

APOLLO ENDOSURGERY-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.